Diabetes Conference | Top Diabetes Medicare Conference | Diabetes Medicare conference

Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 100 Million+ Visitors
  • 75000+ Unique visitors per conference
  • 100000+ Page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Recommended Global Diabetes & Endocrinology Webinars & Conferences

Asia Pacific & Middle East

diabetesmedicare-cs-2020

About Conference

International conference on Diabetes and Diabetic Nurse Education and Practice takes immense pleasure to invite the participants from all over the world to attend this esteemed event which will be hosted at Barcelona, Spain during November 16-17, 2020. This Conference mainly focuses on the theme "Explore New advances in Diabetes and Diabetic Nursing education and Practice".We cordially welcome all the international participants, eminent researchers, students, business entrepreneurs and delegates to take part in this upcoming Diabetes Medicare 2020.

Diabetes is an incessant sickness that happens either when the pancreas does not create enough insulin or when the body can't viably utilize the insulin it produces. Insulin is a hormone that directs glucose. The metabolic disorder is a group of the most risky heart assault hazard factors: diabetes and prediabetes, stomach corpulence, elevated cholesterol and hypertension. In 2014, 8.5% of grown-ups matured 18 years and more established had diabetes. In 2015, diabetes was the immediate reason for 1.6 million passings and in 2012 high blood glucose was the reason for another 2.2 million passings. Hypertension otherwise called hypertension is a long haul ailment where the pulse in the supply routes is tirelessly elevated. Hypertension is a condition that is regularly present in individuals with sort 2 diabetes. It's obscure for what reason there's such a noteworthy relationship between the two illnesses. It's accepted that heftiness, an eating regimen high in fat and sodium, and idleness add to the two conditions.

Benefits to attend Diabetes Medicare 2020:

Medical doctors, patients and health care providers consider the prevention of Diabetes & metabolic syndrome as an essential tool to improve the general health status of the population. The proportions of people suffering from the Diabetes, Hypertension & Metabolic Syndrome are expected to increase in future according a recent statistical survey. Realizing this imperative, Conference Series Ltd is set to organize "International Conference on Diabetes and Diabetic Nurse Education and Practice" for the upcoming year with a view to enhance research and promote awareness aiming in developing solutions for the challenges encountered.

Diabetes Medicare@2020 in Barcelona, Spain:

Barcelona is the central capital and most populous city of Spain. The city has almost 3.3 million inhabitants and a metropolitan area population of approximately 6.5 million. It is the third-largest city in the European Union (EU), surpassed only by London and Berlin, and its monocentric metropolitan area is the third-largest in the EU, smaller only than those of London and Paris. The Barcelonaurban agglomeration has the third-largest GDP in the European Union and its influence in politics, education, entertainment, environment, media, fashion, science, culture, and the arts all contribute to its status as one of the world's major global cities.

Target Audience @ Diabetes Medicare 2020:

  • Diabetes students, Scientists
  • Diabetes Researchers
  • Diabetes Faculty
  • Medical Colleges
  • Diabetes Associations and Societies
  • Business Entrepreneurs
  • Manufacturing Medical Devices Companies
  • Hypertension Societies and Associations
  • Training Institutes
  • Research students
  • Pharma Companies

Conference Opportunities @Diabetes Medicare 2020:

For Researchers and Faculty Members:

  • Speaker Presentation
  • Poster Display
  • Symposium hosting (4-5 member team)
  • Workshop organizing

For Universities, Associations & Societies:

  • Association Partnering
  • Collaboration proposals
  • Academic Partnering
  • Group Participation

For Business Delegates:

  • Speaker Presentations
  • Symposium hosting
  • Book Launch event
  • Networking opportunities
  • Audience participation

For Product Manufacturers:

  • Exhibitor and Vendor Booths
  • Sponsorships opportunities
  • Product launch
  • Workshop organizing
  • Scientific Partnering
  • Marketing and Networking with clients

For Students and Research Scholars:

  • Poster Competition (Winner will get Best Poster Award)
  • Young Researcher Forum (YRF Award to the best presenter)
  • Student Attendee
  • Group Registrations

Scientific Sessions

Scientific Sessions:

Session 1: Type I and Type II Diabetes

Type 1 Diabetes mellitus is a type of diabetes mellitus that outcomes from the immune system annihilation of the insulin-delivering beta cells in the pancreas. The ensuing absence of insulin prompts expanded glucose in the blood and pee. The established manifestations are regular pee, expanded thirst, expanded yearning, and weight reduction. The reason for diabetes mellitus sort 1 is obscure. Type 1 Diabetes can be recognized from type 2 from autoantibody testing. The C-peptide test, which measures endogenous insulin generation, can likewise be utilized.

Type 2 Diabetes is a long haul metabolic turmoil that is portrayed by high glucose, insulin resistance, and relative absence of insulin. Basic side effects incorporate expanded thirst, incessant pee, and unexplained weight reduction. Indications may likewise incorporate expanded craving, feeling tired, and bruises that don't recuperate. Regularly indications go ahead gradually. Long haul complexities from high glucose incorporate coronary illness, strokes, diabetic retinopathy which can bring about visual impairment, kidney disappointment, and poor blood stream in the appendages which may prompt removals.

Session 2: Diagnosis and Treatment of Diabetes 

Diabetes is diagnosed by many tests such as:

Random blood sugar test: This is the primary screening test for type 1diabetes. A blood sample is taken at a random time. Regardless of when your child last ate, a random blood sugar level of 200 milligrams per deciliter (mg/dL), or 11.1 mill moles per liter (mmol/L), or higher suggests diabetes.

Glycated hemoglobin (A1C) test: This test indicates your child's average blood sugar level for the past two to three months. Specifically, the test measures the percentage of blood sugar attached to the oxygen-carrying protein in red blood cells (hemoglobin). An A1C level of 6.5 percent or higher on two separate tests indicates diabetes.

Fasting blood sugar test: A blood sample is taken after your child fasts overnight. A fasting blood sugar level of 126 mg/dL (7.0 mmol/L) or higher indicates type 1 diabetes.

These additional tests include:

Blood tests to check for antibodies that are common in type 1 diabetes

Urine tests to check for the presence of ketones, which also suggests type 1 diabetes rather than type 2

After the diagnosis

Your child will need regular follow-up appointments to ensure good diabetes management and to check his or her A1C levels. The American Diabetes Association recommends an A1C of 7.5 or lower for all children.

Your doctor also will periodically use blood and urine tests to check your child's:

  • Cholesterol levels
  • Thyroid function
  • Kidney function
  • Assess your child's blood pressure and growth
  • Check the sites where your child tests blood sugar and delivers insulin

Your child will need regular eye examinations. Your child also might be screened for celiac disease at the time of diagnosis of diabetes and at intervals afterward, depending on your child's age and symptoms.

Session 3: Endocrine and Metabolic Disorders

Clinical Endocrinology and metabolism is a field of medicine; more precisely a sub-specialty of internal medicine, which mainly deals with the investigation and management of sicknesses related to hormones. The human endocrine system involves number of glands. These glands harvest and release hormones which monitor many important function of our body. When the hormone exits the gland they reach the bloodstream and are moved to organs and tissues in every part of the body. Endocrinology also concentrates on the endocrine glands and tissues that secrete hormones. The human endocrine system comprises of several glands. These glands harvest and secrete hormones which regulate the body's metabolism, growth, sexual development and function. Hormonal imbalance in our body henceforth leads to diabetes.

Session 4: Geriatric Diabetes

Geriatric Diabetes is a chronic, progressive disease that can have serious implications for the well-being of both patients and their families. They may have vision and dexterity problems that interfere with their ability to take their medication. Many may have lost spouses and friends and live on their own, which can contribute to depression and poor eating habits. If older patients are experiencing hypoglycemia, they can be at risk for falls which can further compromise their independence, making diabetes care harder. They evaluates the physical, social and emotional/cognitive status of patients and identifies specific barriers patients and families have in performing diabetes self-management skills.

Each patient undergoes a comprehensive evaluation that includes assessments of:

  • Medical history
  • Medication use
  • Ability to perform self-care behaviors
  • Hypoglycemia severity & frequency
  • Memory
  • Problem solving skills
  • Mood
  • Nutritional intake
  • Physical activity
  • Social background & support system

Session 5: Gestational Diabetes

Gestational diabetes is developed during pregnancy (gestation). Like other types of diabetes, gestational diabetes affects the usage of glucose by cells. High blood sugar can be caused by gestational diabetes and this can affect the pregnancy and the health of baby. Gestational diabetes can be controlled by women by eating healthy foods, exercising and taking medication if necessary. Controlling blood sugar can prevent a difficult birth and can keep both the mother and baby healthy. In gestational diabetes, blood sugar returns to normal soon after delivery. But a person having gestational diabetes can have a risk for type 2 diabetes.

  • Excessive birth weight
  • Early (preterm) birth and respiratory distress syndrome
  • Low blood sugar (hypoglycemia)
  • Type 2 diabetes
  • High blood pressure and preeclampsia
  • Ophthalmologic problem in Diabetes

Session 6: Ophthalmologic problem in Diabetes

Diabetes can also cause a group of eye conditions which are collectively called Diabetic eye disease. The most common form of the disease is diabetic retinopathy which is associated with damage to the tiny blood vessels in the retina. This condition can progress through four stages and eventually result in retinal detachment or permanent vision loss. Other forms of the diabetic eye disease include Glaucoma, Cataracts, Blindness, etc. For early detection and treatment of such disease, it is necessary for affected individuals to undergo retinopathy screening and taking proper care of oneself.

  • Visual Impairment
  • Cataracts
  • Glaucoma
  • Retinal detachment
  • Diabetic Retinopathy
  • Background retinopathy
  • Proliferative retinopathy
  • Diabetic maculopathy

Session 7: Cardiovascular risk in Diabetes

The risk of CVD mortality in type 2 diabetic patients is more than double compared with that in age-matched subjects. Stroke events and all manifestations of CHD, myocardial infarction (MI), sudden death, and angina pectoris is at least twofold more common in patients with type 2 diabetes than in non-diabetic individuals. A high proportion of patients with type 2 diabetes die after an acute MI within 1 year, and a considerable number of patients die outside the hospital. Relative risk for CHD events is higher in female patients with type 2 diabetes than in male patients with type 2 diabetes. The reason for the sex difference is largely unknown but could be at least in part explained by a heavier risk-factor burden and a greater effect of blood pressure and atherogenic dyslipidemia on the risk of CVD in diabetic women than in diabetic men.

  • High Blood Pressure
  • Heart Disease
  • High Blood Glucose
  • Damage of Blood Vessels
  •   Atherosclerosis and Hypertension
  •   Shortness of Breath
  •   Diabetic Neuropathy

Session 8: Diabetic Nursing

Diabetes specialist nurses play a crucial role in screening diabetic persons, detecting early onset of diabetes, assessing nutritional needs of the patient, promoting self-management, providing prevention advice, spreading awareness on diabetes and also providing health coaching. In this context, it is extremely necessary for nurses to be well educated, trained and skilled adequately to be able to proficiently deliver care, support self-management and provide advice to diabetic persons.

  • Diabetic Nursing Education
  • Diabetic Nursing Management
  • Diabetic Nursing Care
  • Diabetic Nursing Assessment
  • Nursing Priorities
  • Nursing Interventions
  • Discharge and Home Care Guidelines

Innovations in Diabetes Research:

  • Vaccination
  • Engineered Beta Cells
  • Artificial Pancreas
  • Islet Neogenesis
  • New Anti-Diabetic Drugs
  • Intensive Combination Therapies
  • Development of Diabetic Diet

Session 9: Diabetes Biomarkers

Molecular Biomarkers can be demarcated as a characteristic that is accurately measured and gauged as an pointer of normal biological procedures, pathogenic procedures, or pharmacologic responses to a pharmaceutical intervention. Biomarkers play a vital part in leading clinical trials and treating patients. Advances in molecular diagnostics help medical professionals make knowledgeable, scientifically valid decisions. More well-organized discovery and usage of biomarkers in the growth of antidiabetes drugs will depend on accelerating our understanding of the pathogenesis of diabetes and specifically its macrovascular complications.  Procedural improvements from other fields, especially cancer, are beginning to show the way towards better models of diabetes pathogenesis and molecular biomarker discovery.

Session 10: Diabetes Management Education

A primary role for nurses is that of a diabetes self-management educator who provides information to patients with pre-diabetes and diabetes in an effort to help patients make informed decisions about prevention and managing their condition. With a focus on helping people make lifestyle changes that contribute to improved health, the duties of a diabetes educator include:

  • Working with patients to assess their needs and to develop a plan that includes educational interventions and self-management support strategies appropriate for the patient
  • Providing education that helps the patient accomplish self-management goals
  • Evaluating patients periodically to determine if they are meeting their goals or if they need other interventions and future reassessments
  • Developing, with the cooperation of the patient, a personalized follow-up plan for ongoing self-management support
  • Documenting the assessment and education plan, as well as interventions and outcomes
  • Diabetes nurse educators provide services in hospitals, physician offices, pharmacies, patients’ homes, and other settings. Advanced practice registered nurses typically serve under a primary specialization in their patient population focus, allowing them to further specialize as adult, gerontological, or pediatric diabetes educators.

Session 11: Diabetic Nursing Education

Certificate programs and nursing continuing education in diabetes management is available for both nurses with an undergraduate degree and for advanced practice nurses who already hold MSNs. These post-baccalaureate and post-graduate certificate programs typically cover the following areas:

  • Pathophysiology, classification, and diagnosis of diabetes mellitus
  • Complications associated with diabetes
  • Oral medications and insulin therapy

Non-drug therapies for diabetes, including exercise, nutrition, and other lifestyle and behavioral modifications. While some MSN programs with a diabetes nursing specialization are available, it is much more common for nurses interested in advanced practice to pursue graduate-level education in a primary patient population focused specialization, such as one designed for adult, pediatric, or family nurse practitioners or clinical nurse specialists. Advanced practice registered nurses interested in diabetic care may take diabetes-related classes during their graduate program, and could arrange to have diabetic care included in the clinical experience component of their education.

Session 12: Diabetes Nurse Educator Certification

Registered Nurses are eligible for certification as Certified Diabetes Educators (CDE) through the National Certification Board for Diabetes Educators. In addition to holding a current, active RN license, nurses must have a minimum of two years of professional experience as an RN. They must also have no fewer than 1,000 hours of experience in diabetes self-management education, with a minimum of 400 hours of experience during the year just before applying for certification, as well as 15 clock hours of continuing education related to diabetes within the two years before applying. The certification exam is given twice a year, in the spring and fall, for a one-month period, through AMP Assessment Centers.

Market Analysis

Scope and importance:

Diabetes is one of the most emerging diseases, which is becoming very common nowadays. Patients with high blood sugar will experience polyuria (frequent urination), meeting thirsty (polydipsia) and hungry (polyphagia). With the change in life style; our endocrine system of the body is getting disturbed. In order to get innovative, the Diabetes Metabolism Conference will focus on the latest and exciting innovations in all areas of diabetes and metabolism based research offering a unique opportunity for international explorers to assemble, network, talk and grasp new scientific innovations and ideas to prevent diabetes related ailments. To allocate advance researches, developments, druggists, scientists, technology challenges and improvement and alternative therapies, this meeting forms an excellent learning.

Business and Economics of Diabetes:

Diabetes has become a lifestyle-related disease as it afflicts young and old. As the proportion of patients are growing rapidly across the globe, there has never been a stronger and more urgent need for novel therapeutic measures in clinical and preclinical evaluation, that arrest the growth of the disease. The diabetes market, consisting of mainly Type 1 and Type 2 diabetes, is large and growing significantly. The global market value for diabetes therapies and diagnostics has aroused to $48.5 billion. The largest segment of the market, insulin products, is worth $20.8 billion in recent days, including administration and diagnostic devices. Diabetes monitoring devices and other related equipment, the second-largest market is established with an investment of $13.5 billion which was proposed for $11.3. The fastest-growing segment of oral diabetic problems of hypoglycemia drugs manufacturing funding is $14.13 in present time scenario of the diabetes market.

Diabetes in America:

Diabetes remains the 7th leading cause of death in the United States in 2015, with 79,535 death certificates listing it as the underlying cause of death, and a total of 252,806 death certificates listing diabetes as an underlying or contributing cause of death.

• In 2015, 30.3 million Americans, or 9.4% of the population, had diabetes. Approximately 1.25 million American children and adults have type-1 diabetes.

• North America is the largest consumption place, with a consumption market share nearly 31.2% in 2017.

Diabetes in Asia:

The prevalence of diabetes is increasing worldwide, particularly in Asia. The Diabetes Atlas published in 2013 reported that 366 million of individuals are affected by diabetes, and 36% of those affected live in the Western Pacific region, with a significant proportion in East Asia.

• The Asia-Pacific market for diabetes drugs is estimated to value USD 23.8 billion in 2019, and the market is expected to grow at the CAGR of 4.82%, during the forecast period.

Diabetes in Middle East and Africa:

According to the International Diabetes Federation Atlas, 19.3 percent of adults aged 20 to 79 in the United Arab Emirates are diabetic. In Bahrain, the percentage rises to 19.6—and the statistic jumps to 20 percent for Kuwait, Qatar, and Saudi Arabia. According to the IDF Diabetes Atlas 8th Edition, approximately 38.7 million adults aged 20-79 years were living with diabetes in the Middle East and North Africa Region in 2017. Over two-thirds (67.3%) of adults with diabetes live in urban areas.

• In Middle East & Africa (MEA), 15.51 million people are suffering from diabetes, and this population is expected to increase in the forecast period with a CAGR of 4.46%.

• The Middle East & Africa diabetes drugs market (henceforth, referred to as the market studied) was valued at USD 2793.99 million in 2018, and it is expected to witness a CAGR of 6.48% during the forecast period 2019 - 2024, primarily due to the growing geriatric population.

Diabetes in Europe:

There are about 60 million people with diabetes in the European Region, or about 10.3% of men and 9.6% of women aged 25 years and over. Prevalence of diabetes is increasing among all ages in the European Region, mostly due to increases in overweight and obesity, unhealthy diet and physical inactivity.

• The European diabetes devices market is expected to record a high CAGR of 7.51% during the forecast period (2019 - 2024), due to the growing prevalence of diabetes, growing geriatric population levels, unhealthy diet, and increasing levels of physical inactivity.

Rising Prevalence of Diabetes

• The market size, in 2017, for the global diabetes drugs market was registered to be USD 67.5 billion, and the market is expected to record a CAGR of 5.65% during the forecast period, 2019-2024.

• As per a WHO report, the global prevalence of diabetes among adults of over 18 years had accelerated from about 4.7%, in 1980, to over 8.5%, in 2014.

• Diabetes prevalence has been rising rapidly in the middle- and low-income countries. In 2015, about 1.6 million deaths were directly associated with diabetes, which was around 2.2 million in 2012.

• Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. WHO projects that diabetes is likely to be the seventh leading cause of death by 2030.

Societies Associated with Diabetes Care:

•    Endocrine Society Australia, Australia

•    American Diabetes Association, Virginia

•    European Society of Endocrinology, UK

•    British Society for Neuroendocrinology, London

•    The American Association of Clinical Endocrinology, Florida

•    British Society for Pediatric Endocrinology and Diabetes, UK

•    British Association of Endocrine and Thyroid Surgeons, London

•    Royal Society of Medicine Endocrinology and Diabetes Section, London

•    Egyptian Association of Endocrinology, Diabetes and Atherosclerosis, Egypt

Global Universities Associated with Diabetes:

Universities in America:

•    University of Alabama, USA

•    Mayo Medical School, USA

•    University of Arizona, USA

•    University of Arizona, USA

•    University of Arkansas, USA

•    California Northstate University, USA

•    Charles R. Drew University of Medicine and Science, USA

•    Keck School of Medicine of University of Southern California, USA

•    Loma Linda University, USA

•    Stanford University, USA

•    University of California, USA

•    George Washington University, USA

•    Florida International University, USA

•    University of Florida, USA

•    University of Calgary, Canada

•    University of Western Ontario, Canada

•    University of Waterloo, Canada

•    University of Montreal, Canada

•    McMaster University, Canada

•    University of Alberta, Canada

•    University of Sao Paulo, Brazil

•    Federal University of Rio De Janeiro, Brazil

•    Sao Paulo State University, Brazil

•    Federal University of Sao Paulo, Brazil

•    Federal University of Rio Grande Do Sul, Brazil

Asia Region

•    The University of Tokyo, Japan

•    National University of Singapore, Singapore

•    Kyoto University, Japan

•    University of Hong Kong, Hong Kong

•    Peking University, China

•    Seoul National University, South Korea

•    National Taiwan University, Taiwan

•    Osaka University, Japan

•    Nanyang Technological University, Singapore

•    Sungkyunkwan University, South Korea

•    Universiti Malaya, Malaysia

•    Indian Institute of Science, India

•    Universiti Kebangsaan Malaysia, Malaysia

•    University of Indonesia, Indonesia

•    Indian Institute of Technology Bombay, India

•    The Hong Kong University of Science and Technology (HKUST), Hong Kong

Middle East Region

•    Arabian Gulf University, Bahrain

•    Faculty of Medicine Zagazig University, Egypt

•    Benha University, Egypt

•    Fayoum Faculty of Medicine, Egypt

•    Bushehr University of Medical Sciences, Iran

•    Dezful University of Medical Sciences, Iran

•    Fasa Faculty of Medical Sciences, Iran

•    University of Kerabala, Iraq

•    University of Duhok, Iraq

•    Thi Qar University, Iraq

•    Minia Medical School, Egypt

•    Royal College of Surgeons in Ireland, Bahrain

•    Fatemiye University of Medical Sciences, Iran

•    Assiut Faculty of Medicine, Egypt

•    Suez Canal Faculty of Medicine, Egypt

Europe Region

•    LMU Munich, Germany

•    Technical University of Munich, Germany

•    University of Leuven, Belgium

•    University of Amsterdam, Netherlands

•    Humboldt University of Berlin, Germany

•    Leiden University, Netherlands

•    Utrecht University, Netherlands

•    Erasmus University Rotterdam, Netherlands

•    RWTH Aachen University, Germany

•    University of Groningen, Netherlands

•    University of Copenhagen, Denmark

•    University of Barcelona, Spain

•    University of Helsinki, Finland

Global Diabetes Research Centers

•    Joslin Diabetes Center, USA

•    Diabetes Research Institute Foundation, USA

•    UCSF Diabetes Center, USA

•    Mayo Clinic, USA

•    Vanderbilt Diabetes Center, USA

•    Euradia, England

•    Dyna Health, Finland

•    Oxford Centre for Diabetes, Endocrinology and Metabolism, England

•    Lundberg Laboratory for Diabetes Research, Sweden

•    German Center for Diabetes Research, Sweden

•    Diabetes Complications Research Centre, Ireland

•    Dubai Diabetes Center, UAE

•    Diabetes Research Center, Japan

•    Imperial College London Diabetes Center, UAE

•    Hong Kong Institute of Diabetes and Obesity, China

•    Korea University Medical Center, South Korea

•    Tel Aviv Sourasky Medical Center, Israel

•    Sheba Medical Center, Israel

•    RAK Diabetes Center, UAE

Global Diabetes-Endocrinology Medicals/Hospitals

America Region

•    Cleveland Clinic, USA

•    Massachusetts General Hospital, USA

•    Johns Hopkins Hospital, USA

•    UCSF Medical Center, USA

•    New York-Presbyterian University Hospital of Columbia and Cornell, Canada

•    Yale-New Haven Hospital, USA

•    Northwestern Memorial Hospital, USA

•    UCLA Medical Center, Canada

•    University of Washington Medical Center, USA

•    Hospitals of the University of Pennsylvania-Penn Presbyterian, USA

•    Brigham and Women’s Hospital, USA

•    Florida Hospital Orlando, USA

•    Cedars-Sinai Medical Center, Canada

•    Barnes-Jewish Hospital/Washington University, USA

•    Beaumont Hospital, USA

•    Mount Sinai Hospital, USA

•   Froedtert Hospital and the Medical College of Wisconsin, USA

•   Lancaster General Hospital, USA

•   University of Kansas Hospital, USA

•    Hospital Municipal Mendez, Argentina

Asian Region

•    Royal Prince Alfred Hospital, Australia

•    Royal Melbourne Hospital, Australia

•    Waikato Hospital, New Zealand

•    Faculty of Medicine Siriraj Hospital, Thailand

•    Prince Court Medical Centre, Malaysia

•    Fortis C-DOC Hospital, India

•    S. L Raheja Hospital, India

•    Apollo Hospitals, India

•    Indraprastha Apollo Hospital, India

•    Manipal Hospital, India

•    Tongji Hospital, China

•    Peking University People's Hospital, China

•    Peking University First Hospital, China

•    Bumrungrad International Hospital, Thailand

•    Bangkok Hospital Medical Center, Thailand

•    Gleneagles Hospital, Singapore

Middle East Region

•    King Faisal Specialist Hospital & Research Centre, Saudi Arabia

•    Riyadh Military Hospital, Saudi Arabia

•    Kbb Istanbul, Turkey

•    Ankara Saglik Müdürlügü, Turkey

•    Medicana Hospital Group, Turkey

•    American Hospital, UAE

•    Bezmi Alem Valide Sultan Vakif Gureba E A Hastanesi, Turkey

•    Hille Yaffe Medical Center, Israel

•    Erfan Hospital, Saudi Arabia

•    Ankara Numone Hospital, Turkey

•    Zulekha Hospital, UAE

•    Denizli Devlet Hastanesi, Turkey

•    King Fahad Medical Ci, Saudi Arabia

Europe Region

•    Swiss Prevention Clinic, Switzerland

•    Klinik Pyramide Am See, Switzerland

•    Health Centre, Switzerland

•    Clinique Générale-Beaulieu, Switzerland

•    Klinik Im Park, Switzerland

•    Klinik Hirslanden, Switzerland

•    Klinik Beau-Site, Switzerland

•    Hirslanden Clinique La Colline, Switzerland

•    Salem-Spital, Switzerland

•    Hirslanden Klinik, Switzerland

•    w. Goethe university hospital, Germany

Global Diabetes-Endocrinology Companies

•    Abbott Diabetes Care, USA

•    Accu-Chek, USA

•    Arkray USA, USA

•    Bayer, USA

•    LifeScan, USA

•    Animas, USA

•    Asante Solutions, USA

•    Abbot Laboratories, USA

•    Amylin Pharmaceuticals, USA

•    Aventis Pharmaceuticals, USA

•    Becton-Dickinson, USA

•    Bristol-Myers Squibb, USA

•    Novo Nordisk, USA

•    Pfizer, USA

•    SmithKline Beecham, USA

•    Takeda Pharmaceuticals, USA

•    Valeant, USA

•    Euradia, UK

•    MedTech Europe, Belgium

•    Cellnovo, France

•    Novo-Nordisk, Denmark

•    Acino, France

•    Thio Matrix -Austria

•    Biocrates, Austria

Conclusion:

European Diabetes market is growing rapidly. Data from the International Diabetes Federation to mark World Diabetes Day in November last year showed that there were 803,900 diabetics in the UAE, about 19 per cent of the population. Middle East Diabetes Market is expected to grow at a CAGR of 5.1% and expected to reach US$ 16.4 billion by 2023 from US$ 11.6 billion in 2016. By 2020, an estimated 32% of the adult population (age 20-79), including both UAE nationals and expatriates, may have diabetes or prediabetes at a possible cost of $8.52 billion (USD) (AED 31.27 billion) over the next decade if current trends continue. Medical costs attributable to diabetes and prediabetes in the UAE are forecast to increase to perhaps $1.04 billion (AED 3.82 billion) by 2020, representing a 58% increase from an estimated $657 million (AED 2.41 billion) in 2010.

References:

1.    https://www.who.int/news-room/fact-sheets/detail/diabetes

2.    https://www.mordorintelligence.com/industry-reports/diabetes-drugs-market

3.    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595349/

4.    https://foodtank.com/news/2016/06/diabetes-rates-are-rising-middle-east/

 

To Collaborate Scientific Professionals around the World

Conference Date November 16-17, 2020

For Sponsors & Exhibitors

sponsor@conferenceseries.com

Speaker Opportunity

Past Conference Report

Supported By

Journal of Diabetic Complications & Medicine Journal of Diabetes & Clinical Practice Journal of Clinical Diabetes

All accepted abstracts will be published in respective Conference Series International Journals.

Abstracts will be provided with Digital Object Identifier by